Siri AI rolls out, but Europe launch is delayed as GSK moves to buy Nuvalent for $10.6 billion in cash
Apple unveiled a new Siri built with generative AI, while EU availability is expected to come later than other regions. In parallel, GlaxoSmithKline agreed to acquire Nuvalent, a cancer-drug developer, in a deal valued at $10.6 billion paid in cash.